|
|
Raltegravir with Optimized Background Therapy for Resistant HIV Infection
In two phase 3 studies, raltegravir was found to be superior to placebo, in the context of optimized background antiviral therapy, in suppressing HIV viral load at 48 weeks (62.1% vs. 32.9%).
Free Full Text
CME Exam
 View an interactive graphic showing HIV structure, life cycle, and drug interaction, and an AIDS timeline.
|
Raltegravir Therapy for Resistant HIV Infection — Subanalyses
In patients with high-risk features for failure of antiretroviral therapy, raltegravir was superior to placebo in terms of a virologic response at 48 weeks. However, among these patients, in whom antiretroviral therapy had been used previously, 23% of raltegravir recipients had virologic failure by 48 weeks.
Free Full Text
|
Variants of SLCO1B1 Associated with Statin-Induced Myopathy
A genomewide screen of patients with myopathy who were taking high-dose simvastatin showed a strong association between myopathy and variants of SLCO1B1, which encodes an organic anion–transporting polypeptide.
 Related Editorial: Pharmacogenomics and Drug Toxicity
|
 July 23, 2008 (DOI: 10.1056/NEJMoa0801936), in Print August 21, 2008 |
Detection of Mutations in EGFR in Circulating Lung-Cancer Cells
This study describes a method for capturing circulating tumor cells in patients with non–small-cell lung cancer with the use of antibody tethered to microposts.
|
| Published Online July 2, 2008 (DOI: 10.1056/NEJMoa0800668) |
Sorafenib in Advanced Hepatocellular Carcinoma
No effective therapy is available for advanced hepatocellular carcinoma. In this trial involving patients with advanced hepatocellular carcinoma, sorafenib improved median survival by 3 months, as compared with placebo.
|
Hypoparathyroidism
A 58-year-old man is found on laboratory testing to have a serum calcium level of 6.0 mg per deciliter, an albumin level of 3.9 g per deciliter, and a phosphorus level of 6.0 mg per deciliter. His ionized calcium level is 0.75 mmol per liter. How should his case be further evaluated and treated?
CME Exam
 Listen to the full text of this article.
|
A Man with Back Pain and a Mass in the Lung
A 26-year-old man experienced the sudden onset of back pain. MRI disclosed a pathologic fracture of the T9 vertebral body. A chest radiograph and CT of the chest showed a mass in the upper lobe of the left lung.
CME Exam
|
Tier 4 Drugs and the Fraying of the Social Compact
The growing number of biologic drugs for cancers and other serious conditions is a harbinger of things to come. Drs. Thomas Lee and Ezekiel Emanuel write that recent headlines about their high costs serve as warnings about the financial and ethical challenges we will increasingly encounter throughout medicine.
|
The Genetic Information Nondiscrimination Act — A Half-Step toward Risk Sharing
Russell Korobkin and Dr. Rahul Rajkumar write that GINA is emblematic of this country’s piecemeal and inconsistent approach to health care policy, which makes little sense and leaves many Americans without access to care or in danger of financial ruin if they seek care.
Free Full Text
Dr. Francis Collins discusses the provisions of the Genetic Information Nondiscrimination Act and its likely effects on patient care and clinical research. Dr. Collins is director of the National Human Genome Research Institute at the National Institutes of Health. (Originally published June 19, 2008.)
|
Shortage of Chemotherapeutic Agents in Iraq
These authors determined the effect of the shortage of chemotherapeutic agents on the outcome of acute lymphoblastic leukemia in Iraqi children during the period of UN sanctions (1990–2002). Many of the children received less than 50% of the prescribed chemotherapy, which was associated with a significantly worse outcome.
Free Full Text
|
|
HIV Integrase Inhibitors — Out of the Pipeline and into the Clinic Free Full Text
Noninvasive Monitoring of Tumors
Published Online July 2, 2008 (DOI: 10.1056/NEJMe0804521)
Sorafenib in Liver Cancer — Just the Beginning
Stents versus Bypass Grafting for Left Main Coronary Artery Disease
Telmisartan, Ramipril, or Both in Patients at High Risk of Vascular Events
Anesthesia Awareness and the Bispectral Index
Violence-Related Mortality in Iraq, 2002–2006 Free Full Text
Slowing the Growth of Health Care Costs
|
|
|
|
|
NEJM Tools
